Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06241846 is registered in ClinicalTrials.gov with MediLink Therapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06241846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06241846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
February 22, 2024
Completion date
February 28, 2029
Enrollment
100 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer (mcrpc)